Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Vir Biotechnology Inc.
Headquarters: San Francisco, CA, United States of America
Website: http://www.vir.bio
Year Founded: 2017
Status: Public
Industry Sector: HealthTechnology
CEO: Marianne de Backer, PhD, MBA
Number Of Employees: 408
Enterprise Value: $103,209,989
PE Ratio: -1.74
Exchange/Ticker 1: NASDAQ:VIR
Exchange/Ticker 2: N/A
Latest Market Cap: $914,743,744
BioCentury | Jan 22, 2025
Product Development
Vir, Sana gain new modality POC: BioCentury’s Clinical Report
Plus readouts from Jasper, Dyne and more
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: Bispecifics poised to enter new era
Decade after first approval, bispecifics on the precipice of going mainstream
BioCentury | Oct 24, 2024
Data Byte
New modalities flood the EGFR pipeline
Bispecifics, ADCs and more compete to become the next-generation of EGFR-targeting agents
BioCentury | Sep 10, 2024
Management Tracks
Vir names Jason O’Byrne CFO
Plus: Maslowski to become CEO of Forge as Miller steps down, and updates from Sofinnova Partners, Abingworth, PATH and more
BioCentury | Sep 4, 2024
Management Tracks
Evers leaving Evotec as CBO
Plus: C-suite changes at Dyne, and updates from Novocure, Amphista, reMYND, Belite Bio, Forward and more
BioCentury | Sep 4, 2024
Product Development
Dyne stumbles on toxicity, leadership concerns
Phase I/II data from exon-skipping DMD therapy show efficacy, but high dose has safety issues
BioCentury | Aug 15, 2024
Finance
No sleep for the biotech bear: Restructurings abound in August
At least 20 companies have trimmed pipelines, cut staff or otherwise re-jiggered strategies in past two weeks to extend runway
BioCentury | Aug 13, 2024
Product Development
Vir evolves from antiviral one-stop shop to protein engineering play
Shedding non-protein platforms and bringing in masked bispecifics for cancer, the company’s pivot highlights the challenges of its founding thesis.
BioCentury | Aug 6, 2024
Deals
Deals Report: Bispecific space continues to foster partnerships
Plus: Otsuka in $800M takeout of Jnana, BioNTech dropping Genmab’s acasunlimab
BioCentury | Jun 11, 2024
Product Development
Clinical Report: Shionogi mulls next steps after underwhelming obesity readout
Plus: Bluejay, Vir give HDV updates; Skye’s miss in glaucoma; and more
Items per page:
1 - 10 of 207